These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 147978)

  • 21. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission.
    Corenblum B; Shaffer EA
    Horm Metab Res; 1989 Dec; 21(12):675-7. PubMed ID: 2559014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Function of dopamine receptors in Parkinson's disease: prolactin responses.
    Laihinen A; Rinne UK
    Neurology; 1986 Mar; 36(3):393-5. PubMed ID: 3081830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hypothalamic dopamine (DA) on salsolinol (SAL)-induced prolactin (PRL) secretion in male goats.
    Jin J; Hara S; Sawai K; Fülöp F; Nagy GM; Hashizume T
    Anim Sci J; 2014 Apr; 85(4):461-7. PubMed ID: 24329779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of dopamine energic pharmacology drugs on secretion of the adrenocorticotropic hormone from the hypophysis.
    Milkov V; Pironcheva G; Miteva K; Russev G; Zlatarev S
    Microbios; 2000; 102(403):155-8. PubMed ID: 10955829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of L-dopa and chlorpromazine on prolactin and growth hormone secretion in normal women.
    Leblanc H; Yen SS
    Am J Obstet Gynecol; 1976 Sep; 126(2):162-4. PubMed ID: 961756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea.
    Caraceni T; Panerai AE; Paratl EA; Cocchi D; Müller EE
    J Clin Endocrinol Metab; 1977 May; 44(5):870-5. PubMed ID: 140180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control.
    Stumpe KO; Kolloch R; Higuchi M; Krück F; Vetter H
    Lancet; 1977 Jul; 2(8031):211-4. PubMed ID: 69827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of Huntington's disease. Blink reflex and levodopa load in presymptomatic and incipient subjects.
    Esteban A; Mateo D; Giménez-Roldán S
    J Neurol Neurosurg Psychiatry; 1981 Jan; 44(1):43-8. PubMed ID: 6451669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parathyroid hormone and calcitonin secretion in man: effect of dopamine agonists and antagonists.
    Williams GA; Kukreja SC; Sethi R; Hargis GK; Bowser EN
    Horm Metab Res; 1986 Jan; 18(1):64-6. PubMed ID: 3949284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrinologic findings in patients with untreated Huntington's chorea.
    Caraceni TA; Parati EA; Giovannini PM; Grassi MP; Scigliano G; Carella F; Müller EE
    Arch Neurol; 1984 May; 41(5):516-20. PubMed ID: 6232913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Model of choreic movement in monkey--contribution for understanding the mechanism of chorea in Huntington's disease].
    Kanazawa I
    Jikken Dobutsu; 1990 Apr; 39(2):168-72. PubMed ID: 2141819
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
    Kobayashi T; Araki T; Itoyama Y; Takeshita M; Ohta T; Oshima Y
    Life Sci; 1997; 61(26):2529-38. PubMed ID: 9416775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition and stimulation of prolactin release. Delayed response in duodenal ulcer patients.
    Rotkvić I; Hrabar D; Krpan H; Banić M; Brkić T; Duvnjak M; Zjacić V; Sikirić P
    Dig Dis Sci; 1992 Dec; 37(12):1815-9. PubMed ID: 1473429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
    De Ceballos ML; Boyce S; Jenner P; Marsden CD
    Eur J Pharmacol; 1986 Nov; 130(3):305-9. PubMed ID: 3792452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
    Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
    Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention.
    Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
    J Psychopharmacol; 2006 Nov; 20(6):789-98. PubMed ID: 16478755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea.
    Müller EE; Parati EA; Panerai AE; Cocchi D; Caraceni T
    Neuroendocrinology; 1979; 28(5):313-9. PubMed ID: 155781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone and prolactin release in Huntington's chorea.
    Chalmers RJ; Johnson RH; Nanda RN
    Lancet; 1977 Oct; 2(8042):824. PubMed ID: 71631
    [No Abstract]   [Full Text] [Related]  

  • 40. Further evidence on the direct action of L-Dopa on prolactin release.
    Donoso AO; Banzán AM; Barcaglioni JC
    Neuroendocrinology; 1974; 15(3-4):236-9. PubMed ID: 4420786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.